Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hezkue Oral Sildenafil Suspension and Alcohol Interaction Study
NCT07302698Phase 1Not yet recruiting
- Sponsor
- Aspargo Laboratories
- Start
- Mar 2026
- Primary completion
- May 2026
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of ASP-001 in erectile dysfunction (ED), sponsored by Aspargo Laboratories. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to Last Quantifiable Concentration at 24 hours and Maximum Observed Plasma Concentration at 24 hours. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
ASP-001
03
Conditions
erectile dysfunction (ED)
Beyond the preview
Go deeper on NCT07302698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07302698.